Sheena Jonathan sold $995K of NTRA

Sheena Jonathan sold 3,150 shares of Natera, Inc. (NTRA) at an average of $316.00 ($304.57–$325.05, $1.00M total) across 19 trades on 2026-11-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Nov 11, 2026, 2:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 2:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The sale represents a modest insider divestment, which may cause short‑term price pressure but is unlikely to affect long‑term valuation.

02

Market read

Primary relevance is the insider sale; broader market impact is limited.

03

What to watch

No new corporate developments accompany the sale; the transaction size is modest relative to NTRA's market cap.

Relevance 4/10Novelty 4/10Timing: post‑filing today

Background

SEC Form 4 filings disclose insider transactions. This filing reports a director's open‑market sale of 3,150 shares at an average price of $316.00.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Director Sheena Jonathan sold $995K of Natera shares via a Form 4 filing on 2026-11-06.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $1M‑scale insider sale by a director is a material but modest signal; investors may view it as a slight negative.

Market effects

Minimal impact on the broader biotech sector; insider sales are common and rarely move the sector.

Limited to U.S. markets where NTRA trades.

Low global relevance.

Counterpoint

The sale could be unrelated to fundamentals; the director may be diversifying without negative implications for the company.

Key entities

  • Natera, Inc.

    US‑listed biotech company (NASDAQ: NTRA).

  • Sheena Jonathan

    Director of Natera who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.

$NTRAMedAI 8/10

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera reported a Q3 2026 adjusted loss of 39 cents per share, wider than expected, but revenues of $794M beat estimates. Oncology and women's health drove growth, with total tests up 34.1% YoY. The company raised 2026 revenue guidance to $3.005B-$3.035B. Gross margin improved, but operating loss narrowed. Cash flow remained positive.